Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …

Introduction: Over the last decade, global health policies and different research areas have
focused on the relevance and impact of medicine shortages. Published studies suggest …

Introduction: South Africa has an appreciable burden of both communicable and non-
communicable diseases as well as high maternal, neonatal, and child morbidity. In recent …

Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

Objectives: Remdesivir has shown promise in the management of patients with COVID-19
although recent studies have shown concerns with its effectiveness in practice. Despite this …

Background: The use of direct oral anticoagulant (DOAC) off-label doses in atrial fibrillation
(AF) patients may result in poor clinical outcomes. However, the true prevalence remains …

Medicines have made an appreciable contribution to improving health. However, even high-
income countries are struggling to fund new premium-priced medicines. This will grow …

Drug shortages have been identified as a public health problem in an increasing number of
countries. This can negatively impact on the quality and efficiency of patient care, as well as …

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …

Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple
initiatives across Europe to lower generic prices and enhance their utilization. However …